(Page 4 of 4)
a statement from the company. Arduro says the designation will speed up the agency’s regulatory review of the therapies. Aduro recently completed a mid-stage trial testing the vaccine combination, and is planning to finish off a second, 240-patient mid-stage study next year.
—San Diego-based Arena Pharmaceuticals (NASDAQ: ARNA) said its German subsidiary has signed an exclusive sales and marketing agreement with Abic, the Israeli subsidiary of Teva Pharmaceuticals, for lorcaserin (Belviq). The deal gives Abic rights to market and distribute lorcaserin in Israel for weight loss or weight management in obese or overweight patients.
—San Diego-based Celladon (NASDAQ: CLDN) gained another gene therapy program for its development pipeline after obtaining an exclusive global license for gene therapy applications of the Stem Cell Factor gene (mSCF) in patients with blocked coronary arteries. Celladon, which is also advancing a gene therapy for heart failure, said it obtained the license from one of its investors, San Diego’s Enterprise Partners Venture Capital.
—Xconomy Deputy Biotech Editor Ben Fidler contributed to this roundup.